Aligos Therapeutics Inc (ALGS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 44.35 is considered Undervalued compared with the five-year average of -2.78. The fair price of Aligos Therapeutics Inc (ALGS) is between 49.89 to 54.06 according to relative valuation method. Compared to the current price of 6.96 USD , Aligos Therapeutics Inc By Undervalued By 86.04%.

Relative Value

Fair Zone

49.89-54.06

Current Price：6.96

86.04%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Aligos Therapeutics Inc (ALGS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Aligos Therapeutics Inc (ALGS) has a current Price-to-Book (P/B) ratio of 0.78. Compared to its 3-year average P/B ratio of 1.10, the current P/B ratio is approximately -28.90% higher. Relative to its 5-year average P/B ratio of 2.79, the current P/B ratio is about -71.94% higher. Aligos Therapeutics Inc (ALGS) has a Forward Free Cash Flow (FCF) yield of approximately -141.56%. Compared to its 3-year average FCF yield of -108.54%, the current FCF yield is approximately 30.42% lower. Relative to its 5-year average FCF yield of -79.16%, the current FCF yield is about 78.83% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ALGS competitors is 1328.72, providing a benchmark for relative valuation. Aligos Therapeutics Inc Corp (ALGS.O) exhibits a P/S ratio of 44.35, which is -96.66% above the industry average. Given its robust revenue growth of -41.61%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ALGS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ALGS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ALGS currently overvalued or undervalued?

Aligos Therapeutics Inc (ALGS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 44.35 is considered Undervalued compared with the five-year average of -2.78. The fair price of Aligos Therapeutics Inc (ALGS) is between 49.89 to 54.06 according to relative valuation method. Compared to the current price of 6.96 USD, Aligos Therapeutics Inc is Undervalued By 86.04%.

What is Aligos Therapeutics Inc (ALGS) fair value?

ALGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Aligos Therapeutics Inc (ALGS) is between 49.89 to 54.06 according to relative valuation method.

How does ALGS's valuation metrics compare to the industry average?

The average P/S ratio for ALGS's competitors is 1328.72, providing a benchmark for relative valuation. Aligos Therapeutics Inc Corp (ALGS) exhibits a P/S ratio of 44.35, which is -96.66% above the industry average. Given its robust revenue growth of -41.61%, this premium appears unsustainable.

What is the current P/B ratio for Aligos Therapeutics Inc (ALGS) as of Mar 03 2026?

As of Mar 03 2026, Aligos Therapeutics Inc (ALGS) has a P/B ratio of 0.78. This indicates that the market values ALGS at 0.78 times its book value.

What is the current FCF Yield for Aligos Therapeutics Inc (ALGS) as of Mar 03 2026?

As of Mar 03 2026, Aligos Therapeutics Inc (ALGS) has a FCF Yield of -141.56%. This means that for every dollar of Aligos Therapeutics Inc's market capitalization, the company generates -141.56 cents in free cash flow.

What is the current Forward P/E ratio for Aligos Therapeutics Inc (ALGS) as of Mar 03 2026?

As of Mar 03 2026, Aligos Therapeutics Inc (ALGS) has a Forward P/E ratio of -1.17. This means the market is willing to pay $-1.17 for every dollar of Aligos Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Aligos Therapeutics Inc (ALGS) as of Mar 03 2026?

As of Mar 03 2026, Aligos Therapeutics Inc (ALGS) has a Forward P/S ratio of 44.35. This means the market is valuing ALGS at $44.35 for every dollar of expected revenue over the next 12 months.

ALGS Valuation